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Abstract: The foramen ovale, an atrial septal defect, which is essential in the fetal circulation, remains patent through adulthood in ap-
proximately 25% of the general population and therefore it represents the most common persistent abnormality of fetal origin. Patent fo-
ramen ovale (PFO) allows interatrial right-to-left blood shunting during those periods of the cardiac cycle in which the right atrial pres-
sure exceeds the left one. 
An increasing number of pathological manifestations of PFO has been recently identified; among these, paradoxical systemic embolism, 
refractory hypoxemia in patients with right ventricular myocardium infarction or severe pulmonary disease, orthostatic oxygen desatura-
tion in the rare platypnea-orthodeoxia syndrome, neurological decompression illness in divers, high altitude pilots and astronauts, and fi-
nally, migraine headache with aura.  
Nowadays, many techniques allow to detect a PFO. In this study, we investigated each of them, assessing their potential diagnostic role 
even in comparison with the main features of the other methods. 
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INTRODUCTION 
 The patent foramen ovale (PFO) is a congenital heart defect 
caused by a non-fusion of the two interatrial fetal septa (septum 
primum and septum secundum). This anatomic variant may be 
found in approximately 10% of the healthy adult population [1-3] 
and therefore it REPRESENTS the most common persistent ab-
normality of fetal origin. Patent foramen ovale (PFO) allows in-
teratrial right-to-left blood shunting during those periods of the car-
diac cycle in which the right atrial pressure exceeds the left one [2-
7]. This anatomic defect has been recently associated with an in-
creasing number of pathological manifestations; among these are, 
paradoxical systemic embolism (which can determinate cryptoge-
netic ischemia, mostly in young patients), neurological decompres-
sion illness in divers, high altitude pilots and astronauts, platypnea-
orthodeoxia syndrome (characterized by orthostatic oxygen desatu-
ration and dyspnea, followed by a clinostatic increase of the O2 
saturation), and finally, migraine headache with aura. 
 In patients under 55 years old, up to 40% of ischemic strokes is 
classified as cryptogenetic strokes, that is, strokes without evidence 
of an cardiac or epiaortic emboligenic source and with a lesion dis-
tribution which does not suggest intracranic small vessels disease 
[4-9]. 
 A causal relationship between PFO and brain ischemia is still 
uncertain, but many studies showed a statistical significant link be-
tween PFO prevalence or/and interatrial septum aneurism and cryp-
togenetic ictus, in comparison to the control arm [3-13]. 
 Recent researches also showed the presence of recurrent head-
ache in patients with PFO and right-to-left shunt: the pathogenetic 
hypothesis of this phenomenon seems to be linked to the genesis of 
paradoxical emboli which produce microischemia areas inducing 
headache [4-9, 13-18]. 
 Because of these new pathophisiological hypothesis, the re-
search of a PFO extended to a larger part of population than in the 
past and this requires the identification of diagnostic methods which 
would be not-expansive, not-invasive and, at the same time, highly 
sensitive and specific.  
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TRANSTHORACIC ECHOCARDIOGRAPHY 
 Transthoracic ultrasound is a not-expansive diagnostic method 
which can be indiscriminately applied to all patients, but it has a 
low sensitivity [4-13]. Actually, it allows to detect, by doppler ve-
locimetric method, an IAS shunt only in those patients in which the 
defect is large, but leaving to operator a diagnostic doubt in the rest 
of individuals. 
 Other important limits of this technique are its inability to de-
terminate the shunt direction (from left to right or vice versa) and 
the quality of patient’s ultrasound window (Fig. 1). 
 Vein contrast injection (shaken saline solution) during the per-
formance of the ecocardiographic examination can increase its sen-
sitivity.  
TRANSCRANIC ULTRASONOGRAPHY 
 Transcranic ultrasonography is a diagnostic method which 
nowadays represents a fascinating alternative to transthoracic ultra-
sound in detecting PFO. 
 It allows to visualize the passage of air microbubbles in the 
cerebral arterial circle after injection of shaken physiologic solution 
into a peripheral vein [19], and therefore it indirectly shows the 
presence of a right-to-left blood shunting. Its sensitivity is compa-
rable to the transesophageal ecocardiography’s one, but transcranic 
ultrasonography does not allow to distinguish the intracardiac 
shunts from the extracardiac ones. 
 At cerebral media artery or temporal artery level, microbubbles 
can be observed and counted out one by one, during their passage. 
The recorded signal associated to this passage can individuate the 
dimension of the defect. To increase the sensitivity of the examina-
tion, patient is requested to perform the Valsalva maneuver, so that 
the venous return to the heart increases, the resistance offered to 
blood ejection from pulmonary vessels enhances and, subsequently, 
the septum secundum can grow away from the septum primum, 
making the shunt more visible [20]. 
 Some method-principles have to be pointed out: the Valsalva 
maneuver must be performed about 5’’ after the contrast injection, 
because it was demonstrated that a solution injected into a periph-
eral vein requires almost this time to reach the heart: thus, it would 
be non-sense to perform the maneuver earlier or even before inject-
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ing the shaken physiological solution. On the contrary, it remains 
still uncertain which is the actual latency time spent by microbub-
bles to reach the temporal artery, meaning that the examination re-
sult is positive: 3 cardiac cycles, 10 seconds or 20 seconds? 
 In literature, the sensitivity of the transcranic ultrasonography 
varies from 63% to about 90%. 
 It was demonstrated that the best results in terms of sensitivity 
and specificity can be obtained when the examination is repeated at 
least twice, the operator waits for at least 40 seconds the possible 
passage of microbubbles and any threshold value is not considered 
about the number of microbubbles eventually visualized [21]. 
 However, the specificity of this technique is not high and there-
fore, in our practice experience, we use it as a screening method 
(Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Transthoracic ultrasound in a patient affected by PFO.  
It is possible to detect as the IAS’s central part has become more thin then normal, level with the fossa ovalis, with bloodstream going through the same in-
teratrial septum. 
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TRANSESOPHAGEAL ECHOCARDIOGRAPHY WITH OR 
WITHOUT CONTRAST 
 Transesophageal echocardiography is a high-sensitivity and 
specificity diagnostic method therefore it allows a more accurate 
anatomic and functional characterization of the interatrial septum 
and foramen ovale than the other echocardiographic techniques de-
scribed so far, sometimes evidencing already at baseline a non-
fusion between the septum primum and the septum secundum. 
 The use of color-doppler technique makes this method highly 
sensible by evidencing the right-to-left shunt as a slower flow 
through the interatrial septum, even if this abnormality can be de-
tected only in 30% of cases [17-19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Transcranic ultrasonography.  
It is possible to notice in the lower panel the presence of air microbubbles altering the Doppler spectrum of the upper panel. These microbubbles appeared 
about 10’’ after injection of a shaken saline solution in a peripheral vein.  
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 During the transesophageal echocardiography, it is possible to 
perform the Valsalva maneuver, so that the blood pressure increases 
in the right atrium and the shunt becomes more visible at color-
doppler evaluation. 
 Moreover, this examination overcomes the obstacle of a low-
quality ultrasound window but, because it is invasive, not all pa-
tients accept it (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Image of an interatrial septum in a transesophageal exam per-
formed at baseline (upper panel) and after injection of shaken physiologic 
solution (lower panel).  
In the second panel it is possible to notice an abnormal passage of contrast 
medium into the left atrium, after opacification of the right one.  
 
CONTRAST ECHOCARDIOGRAPHY 
 By this method, after injecting a shaken physiologic solution 
(contrast medium), PFO can be detected if microbubbles are visual-
ized in the left heart chambers within three cardiac cycles from the 
full opacification of the right atrium [18]. 
 Contrast saline injection increases the sensitivity of the exami-
nation and it may be accompanied by performance of the Valsalva 
maneuver. The choice of the contrast injection site has also a the 
diagnostic relevance: in most cases, a venous access sited in the 
superficial venous circle of the upper limb is chosen, so that con-
trast medium is injected into the superior vena cava territory.  
 In this way, as soon as bloodstream comes in the right atrium, it 
heads for the foramen ovale, favoring identification of the possible 
right-to-left shunt, therefore, increasing the sensitivity of the diag-
nostic technique. 
 The sensitivity of this method resulted very low (about 64%) in 
many studies carried out about 10 years ago by different Authors; 
indeed, in a more recent sensitivity assessment, it was referred 
equal to 90%, with a specificity of 95% [18]. 
 Variations in sensitivity and specificity likely depend both on 
operator’s ability / experience and technical difficulty in visualizing 
images useful for the diagnosis, mostly in patients with a very bad 
ultrasound window (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Two frames in succession of a transthoracic ultrasound performed 
after injection of shaken saline solution in a patient with PFO. 
It is possible to detect an abnormal presence of microbubbles in the left 
heart within a few seconds from the contrast injection in a peripheral vein.  
COMPUTED TOMOGRAPHY (TC) 
 This examination allows visualizing PFO only after injection of 
a contrast medium, thanks to the early opacification of the left 
atrium [22,23]. It has neither higher sensitivity nor higher specific-
ity then the transesophageal echocardiography and it requires a con-
siderable quantity of ionizing radiations: therefore, nowadays it is 
not used as a diagnostic method.  
NUCLEAR MAGNETIC RESONANCE (NMR) 
 Till a few years ago, NMR was not employed in the diagnosis 
of PFO because of its low temporal and spatial resolution capacity; 
transesophageal echography certainly represented the most accurate 
technique, but this allowed the heart visualization during the pas-
sage of contrast medium along an only plain. After injection of the 
contrast solution, NMR seems able to detect an interatrial shunt by 
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opacificating the left atrium before the pulmonary vein [22-27] 
(Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Anatomical images in a NMR performed without contrast medium. 
The upper panel shows a PFO while the lower one shows a large interatrial 
defect causing a remarkable right-to-left shunt and a dilatation of the right 
atrium. The accurate anatomical resolution of this diagnostic technique at 
baseline allows to visualize perfectly the interatrial septum.  
 
 This diagnostic method is still scarcely employed to detect PFO 
and in the future more accurate images will be likely obtained by 
using techniques which allow a three-dimensional study of the 
heart.  
3-DIMENSIONAL ECHOCARDIOGRAPHY  
 3-dimensional echocardiography offers many different advan-
tages, compared with usual echocardiographic techniques. 
First of all, it allows to make a diagnosis already at baseline (with-
out the use of contrast medium), because it guarantees a detailed 
reconstruction of the heart by using all the three spatial dimensions; 
moreover, it is possible to perform the examination in real time or 
to revise images afterwards, sparing patient long and exhausting 
diagnostic meetings. During reconstruction, this method allows to 
analyze separately each of the 3 spatial dimensions, assessing 
movements of the interatrial septum during both systole and dias-
tole. 
 Because of the high specificity of this method, even if any study 
has not been published in the literature as yet, on the basis of our 
own experience, we think 3-dimensional echocardiography will be 
the “gold standard” diagnostic technique for detecting PFO in the 
future. Actually, it does not need any venous access and subse-
quently, it does not require at least two operators, unlike the con-
trast-enhanced instrumental methods; moreover, because it uses a 
transthoracic probe, 3-dimensional echocardiography is not inva-
sive, and so it is more tolerated by patient then the transesophageal 
ultrasound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Post-processing reconstruction of a 3-dimensional transthoracic 
ultrasound.  
It is possible to visualize an abnormal movement of the IAS toward the left 
atrium: the septum is not visible in the first frame (upper panel) and it ap-
pears in the second one (lower panel). The two frames were performed in 
succession, with an interval of about 600 ms. 
 
 The only limit of this method is the image quality, especially in 
patients with a suboptimal echocardiography window, but there is 
no doubt that it can be significantly improved thanks to the use of a 
3-dimensional probe (Fig. 6). Anyway, it is possible to increase the 
sensitivity of 3-dimensional echocardiography by injecting a con-
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trast medium (shaken saline solution) to visualize directly in a 
three-dimensional way and the passage of air microbubbles through 
a PFO. 
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